Twitter Shreds Drug Profiteer as Price Rise Scandal Goes National

Former hedge-fund manager Martin Shkreli is coming under fire after Andrew Pollack published an unflattering profile of his company, Turing Pharmaceuticals, on Sunday.


The article hinged on the fact that Turing purchased Daraprim, used to treat life-threatening parasitic infections in pregnant women and immunocompromised individuals, and immediately raised the price of the drug from $13.50 per dosage to $750. Shkreli claimed that the drug is used so infrequently that it would have minimal impact on the health care system.

“This isn’t the greedy drug company trying to gouge patients, it is us trying to stay in business,” he said, adding that most individuals on the drug are receiving doses for short periods of time, and that the new price better reflects the rarity with which it is prescribed.

“This is still one of the smallest pharmaceutical products in the world,” he said. “It really doesn’t make sense to get any criticism for this.”

Needless to say, not only does it make perfect sense for him to be receiving criticism “for this,” he’s getting quite a bit of it:

[[{"type":"media","view_mode":"full","fid":"603351","attributes":{"alt":"","class":"media-image","height":"480","typeof":"foaf:Image","width":"433"}}]]

[[{"type":"media","view_mode":"full","fid":"603352","attributes":{"alt":"","class":"media-image","height":"346","typeof":"foaf:Image","width":"480"}}]]

[[{"type":"media","view_mode":"full","fid":"603353","attributes":{"alt":"","class":"media-image","height":"480","typeof":"foaf:Image","width":"420"}}]]

[[{"type":"media","view_mode":"full","fid":"603354","attributes":{"alt":"","class":"media-image","height":"480","typeof":"foaf:Image","width":"400"}}]]

They no doubt approve of his favorite method of dealing with criticism — quoting rappers:

[[{"type":"media","view_mode":"full","fid":"603355","attributes":{"alt":"","class":"media-image","height":"319","typeof":"foaf:Image","width":"480"}}]]

Watch Shkreli speak to Bloomberg Business about the reaction to his decision below:

Enjoy this piece?

… then let us make a small request. AlterNet’s journalists work tirelessly to counter the traditional corporate media narrative. We’re here seven days a week, 365 days a year. And we’re proud to say that we’ve been bringing you the real, unfiltered news for 20 years—longer than any other progressive news site on the Internet.

It’s through the generosity of our supporters that we’re able to share with you all the underreported news you need to know. Independent journalism is increasingly imperiled; ads alone can’t pay our bills. AlterNet counts on readers like you to support our coverage. Did you enjoy content from David Cay Johnston, Common Dreams, Raw Story and Robert Reich? Opinion from Salon and Jim Hightower? Analysis by The Conversation? Then join the hundreds of readers who have supported AlterNet this year.

Every reader contribution, whatever the amount, makes a tremendous difference. Help ensure AlterNet remains independent long into the future. Support progressive journalism with a one-time contribution to AlterNet, or click here to become a subscriber. Thank you. Click here to donate by check.

Close
alternet logo

Tough Times

Demand honest news. Help support AlterNet and our mission to keep you informed during this crisis.